LeapeLLCullenDJClappMD. Pharmacist participation on physician rounds and adverse drug events in the intensive care unit. JAMA. 1999;282(3):267–270.
2.
RivkinAYinH. Evaluation of the role of the critical care pharmacist in identifying and avoiding or minimizing significant drug-drug interactions in medical intensive care patients. J Crit Care. 2011;26(1):104e101–104e106.
3.
LouzonPJenningsHAliM. Impact of pharmacist management of pain, agitation, and delirium in the intensive care unit through participation in multidisciplinary bundle rounds. Am J Health Syst Pharm. 2017;74(4):253–262.
4.
ShulmanRMcKenzieCALandaJ. Pharmacist’s review and outcomes: treatment-enhancing contributions tallied, evaluated, and documented (PROTECTED-UK). J Crit Care. 2015;30(4):808–813.
5.
SmithburgerPLPatelMK. Pharmacologic considerations surrounding sedation, delirium, and sleep in critically Ill adults: a narrative review. J Pharm Pract. 2019;32(3):271–291.
6.
WampoleCRSmithKE. Beyond opioids for pain management in adult critically Ill patients. J Pharm Pract. 2019;32(3):256–270.
7.
BuckleyMSDzierbaALMuirJ. Moderate to severe acute respiratory distress syndrome management strategies: a narrative review. J Pharm Pract. 2019;32(3):347–360.
8.
TorbicH. Management of pulmonary arterial hypertension in the ICU. J Pharm Pract. 2019;32(3):303–313.
9.
DastaJFGillSK.Review of the Literature on the Costs Associated With Acute Kidney Injury. J Pharm Pract. 2019;32(3):292–302.
10.
LamSWBassSN. Advancing infectious diseases diagnostic testing and applications to antimicrobial therapy in the ICU. J Pharm Pract. 2019;32(3):327–338.
11.
ProcopioGLPatelR. Clinical Pearls in Medical Toxicology: Updates Ranging From Decontamination to Elimination. J Pharm Pract. 2019;32(3):339–346.
12.
JacobiJ. Management of endocrine emergencies in the ICU. J Pharm Pract. 2019;32(3):314–326.
